Structure-based design, synthesis, and evaluation of inhibitors with high selectivity for PARP-1 over PARP-2
- 1 January 2022
- journal article
- research article
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 227, 113898
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Nanoparticle-mediated delivery of siRNA targeting Parp1 extends survival of mice bearing tumors derived from Brca1-deficient ovarian cancer cellsProceedings of the National Academy of Sciences, 2010
- The PARP Side of the Nucleus: Molecular Actions, Physiological Outcomes, and Clinical TargetsMolecular Cell, 2010
- Discovery of 2-{4-[(3S)-Piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): A Novel Oral Poly(ADP-ribose)polymerase (PARP) Inhibitor Efficacious in BRCA-1 and -2 Mutant TumorsJournal of Medicinal Chemistry, 2009
- 4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1Journal of Medicinal Chemistry, 2008
- Toward specific functions of poly(ADP-ribose) polymerase-2Trends in Molecular Medicine, 2008
- Feedback-regulated poly(ADP-ribosyl)ation by PARP-1 is required for rapid response to DNA damage in living cellsNucleic Acids Research, 2007
- Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymeraseNature, 2005
- The PARP superfamilyBioEssays, 2004
- Poly(ADP-ribose) Polymerase-2 (PARP-2) Is Required for Efficient Base Excision DNA Repair in Association with PARP-1 and XRCC1Journal of Biological Chemistry, 2002
- PARP-2, A Novel Mammalian DNA Damage-dependent Poly(ADP-ribose) PolymeraseJournal of Biological Chemistry, 1999